You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
星湖科技(600866.SH):利巴韋林原料藥收入對公司營收影響極小
格隆匯 02-05 19:23

格隆匯2月5日丨星湖科技(600866.SH)公佈,公司股票於2020年2月3日、4日、5日連續三個交易日漲幅偏離值累計達19.72%

經公司自查,公司目前生產經營活動正常,日常經營情況未發生重大變化,內部生產經營秩序正常。但受疫情影響,部分省市根據各省市相關政策存在開工延後等情況,由於部分供應商延期復工和物流不暢及其他因素影響,將對公司未來的生產經營產生一定影響,影響程度暫時無法確定。目前公司正在通過多方積極協調,根據疫情及市場變動適時調整生產經營策略等方式,進一步降低本次疫情帶來的影響。

公司關注到近日市場有對公司生產的利巴韋林原料藥產品的傳聞,現對相關情況説明並風險提示如下:

利巴韋林(俗稱病毒唑)是一種廣譜抗病毒藥物。公司生產的利巴韋林原料藥,是提供給下游醫藥製造企業生產藥品的原料。公司2019年1-9月合併報表銷售收入84469.10萬元,其中:利巴韋林原料藥銷售收入為1910.94萬元,佔公司同期營業收入的2.26%,該原料藥的銷售收入對公司營業收入影響極小,對公司整體經營業績影響較小。

利巴韋林原料藥產品為下游製藥企業的原材料,其銷售需視下游企業及市場的需求而定,其產品的最終用途由下游企業來安排。截止目前,利巴韋林原料藥產品尚未對公司業績產生重大影響,敬請廣大投資者注意投資風險。公司將會按照政府相關部門的要求和客户訂單的需求,做好相關產品的生產經營安排,全力保障市場供應,以實際行動支持防控工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account